TG Therapeutics, Inc.

NEWS

Business

TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD

April 29, 2020

·

5 min read

Job Trends

Clinical Catch-Up: April 20-24

April 24, 2020

·

10 min read

·

Pharm Country

TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting

March 9, 2020

·

4 min read

FDA

TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Follicular Lymphoma

March 5, 2020

·

6 min read

Business

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial ResultsConference call to be held today, Tuesday, March 3, 2020 at 8:00 AM ET

March 3, 2020

·

11 min read

Business

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2019 Financial Results and Business UpdateInvestor Conference Call to be held Tuesday, March 3, 2020 at 8:00 AM ET

February 28, 2020

·

1 min read

Pharm Country

TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma

January 16, 2020

·

5 min read

Pharm Country

TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferencePresentation scheduled for Thursday, January 16, 2020 at 8:00 AM PT

January 10, 2020

·

1 min read

Pharm Country

TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional InvestorCompany anticipates ending 2019 with approximately $140 million in cash, providing funding well into 2021

December 23, 2019

·

5 min read

Pharm Country

TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent & in Triple Combination with Ublituximab & Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting & Exposition

December 9, 2019

·

9 min read

Pharm Country

TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition

December 8, 2019

·

7 min read

Pharm Country

TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition

December 6, 2019

·

5 min read

Pharm Country

TG Therapeutics to Present at the Jefferies London Healthcare ConferencePresentation scheduled for Wednesday, November 20, 2019 11:20 AM GMT

November 18, 2019

·

1 min read

Business

TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial ResultsConference call to be held today, Tuesday, November 12, 2019 at 8:30 AM ET

November 12, 2019

·

11 min read

Business

TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business UpdateConference Call to be held Tuesday, November 12, 2019 at 8:30 AM ET

November 8, 2019

·

2 min read

TG Therapeutics Announces Triple Combination Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition

November 6, 2019

·

8 min read

AWARDS

JOBS